Zobrazeno 1 - 10
of 905
pro vyhledávání: '"Östör, A."'
Autor:
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 633-648 (2024)
Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had
Externí odkaz:
https://doaj.org/article/9ce4042ecece4341be994d1a7b7901c4
Autor:
Östör, Andrew1,2,3 (AUTHOR) andrewostor@gmail.com, Van den Bosch, Filip4,5 (AUTHOR), Papp, Kim6,7 (AUTHOR), Asnal, Cecilia8 (AUTHOR), Blanco, Ricardo9 (AUTHOR), Aelion, Jacob10 (AUTHOR), Carter, Kyle11 (AUTHOR), Stakias, Vassilis11 (AUTHOR), Lippe, Ralph11 (AUTHOR), Drogaris, Leonidas11 (AUTHOR), Soliman, Ahmed M.11 (AUTHOR), Chen, Michael M.11 (AUTHOR), Padilla, Byron11 (AUTHOR), Kivitz, Alan12 (AUTHOR)
Publikováno v:
Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p633-648. 16p.
Autor:
Rieke Alten, Gerd R. Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J. M. Brnabic, Bruno Fautrel
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1575-1595 (2023)
Abstract Introduction RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment along with patient baseline characteristics. Thi
Externí odkaz:
https://doaj.org/article/63d5ff311b2441d18921c0a0894d1ffb
Autor:
Xenofon Baraliakos, Roberto Ranza, Andrew Östör, Francesco Ciccia, Laura C. Coates, Simona Rednic, Jessica A. Walsh, Kevin Douglas, Tianming Gao, Koji Kato, In-Ho Song, Fabiana Ganz, Atul Deodhar
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. Methods Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients ran
Externí odkaz:
https://doaj.org/article/90d18e6abacf401699f4e7aeeb68ccd1
Autor:
Victoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, Andrew Östör, Christopher D. Saffore, Manish Mittal, In-Ho Song, Fabiana Ganz, Jayne Stigler, Atul Deodhar
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 3, Pp 679-691 (2023)
Abstract Introduction Patients with ankylosing spondylitis (AS) have significant unmet treatment needs, despite advancements in biologic therapies. This study evaluated the impact of upadacitinib on clinically meaningful improvement in patient-report
Externí odkaz:
https://doaj.org/article/4c4e65cdcd924c5cbdacdf4e4e9d1654
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrew Östör
Publikováno v:
Journal of Clinical Rheumatology and Immunology, Vol 24, Iss supp01, Pp 8-8 (2024)
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the axial skeleton, encompassing both radiographic and non-radiographic forms. The disease is characterized by chronic back pain and spinal stiffness, which are
Externí odkaz:
https://doaj.org/article/db71e9e8e9b34323962ff30727e7f892
Autor:
Andrew Östör
Publikováno v:
Journal of Clinical Rheumatology and Immunology, Vol 24, Iss supp01, Pp 7-7 (2024)
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that is associated with psoriasis (PsO) and affects about 20% of patients with psoriasis. PsA is characterized by a wide range of symptoms that can vary over time, affecting both the muscu
Externí odkaz:
https://doaj.org/article/ee07f196e25f4dfe98ad54f5e87818a7
Autor:
Désirée van der Heijde, Filip van den Bosch, Atul Deodhar, Joachim Sieper, Bernard Combe, Walter P Maksymowych, In-Ho Song, Tae-Hwan Kim, Mitsumasa Kishimoto, Yuanyuan Duan, Yunxia Sui, Andrew J Östör, Peter K Wung
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at wee
Externí odkaz:
https://doaj.org/article/70da74d6d0eb473ab12c42387a181ffd
Publikováno v:
Journal of Radioanalytical & Nuclear Chemistry; Jul2024, Vol. 333 Issue 7, p3325-3333, 9p